The Effect of Tenofovir Treatment on Renal Function in Chronic Hepatitis B Patients

Abstract

INTRODUCTION: It is known that chronic hepatitis B virus (HBV) infection is associated with chronic kidney disease. The agents used in the treatment of chronic HBV are safe and well tolerated, but their long-term side effects are largely unknown. We aimed to investigate the effects of antiviral treatments on renal function in patients with chronic HBV follow-up. METHODS: In this study, 156 patients who were followed-up with the diagnosis of chronic HBV in the outpatient clinic of our hospital between 2013-2019 were included. Demographic data of all patients (age, sex), anthropometric characteristics, disease duration, duration of treatment, which antiviral treatment was taken and body mass index were documented. Serum samples were taken from the patients for laboratory analysis before and after treatment. RESULTS: While 92(58.9%) of the patients were male, the mean age of the patients was 48.47+-15.1. Mean duration of disease was 91.8+-13.6 and mean duration of treatment was 54.9+-13.6. There was no significant difference between the antiviral groups in terms of demographic data, anthropometric measurements and liver function tests (p>0.05). In addition, there was no statistically significant difference between the treatment groups in the laboratory measurements performed before and after treatment (p> 0.05). DISCUSSION AND CONCLUSION: In our study, there was no significant change in renal functions before and after treatment in groups receiving antiviral therapy. However, it is recommended that individuals with chronic HBV who have risk factors such as basal renal dysfunction and comorbidity accompany renal function closely during the Tenofovir treatment.

Keywords

• antiviral therapy
• chronic hepatitis b
• renal function